Qian Yining, Lin Jie, Duan Hongxia, Luo Yongting, Feng Liqun
Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Email:
Zhonghua Yi Xue Za Zhi. 2014 Nov 25;94(43):3392-6.
To explore the relationship between circulating level of soluble CD146 (sCD146) and plaque vulnerability or inflammatory factors in patients with carotid atherosclerosis (CAS).
Forty CAS patients with carotid stenosis ( ≥ 70%) were enrolled and divided into 2 groups of stable and unstable plaque by ultrasonic imaging. And another 40 healthy subjects were enrolled for control group. Double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) was employed to measure the serum levels of sCD146 and matrix metalloproteinase-9 (MMP-9), analyze the correlation of sCD146 with MMP-9 and high sensitivity CRP (hs-CRP), and evaluate whether sCD146 correlates with plaque vulnerability.
Soluble CD146 level was elevated in CAS patients versus healthy donors [(212 ± 43) vs (173 ± 36) ng/ml, P < 0.001]. And sCD146 level significantly increased in CAS patients with unstable plaques than those with stable plaque [(218 ± 28) vs (176 ± 25) ng/ml, P < 0.001]. And sCD146 was correlated with high-sensitivity C-reactive protein (hsCRP, r = 0.370 9, P = 0.018 5), a well-known marker for CAS inflammation. Also it was an independent risk factor for plaque vulnerability (OR = 1.16, 95%CI:1.020-1.310, P = 0.019 2). And its level was not correlated with the risk factors of CAS, such as age, homocysteine, triglyceride, total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C) or high density lipoprotein-cholesterol (HDL-C) (P > 0.05). But there was a good correlation with the serum level of MMP-9 in CAS patients (r = 0.677 2, P < 0.001).
The concentration of soluble CD146 is positively correlated with hsCRP and MMP-9 in CAS patients. And inflammation and neovascularization may interact with each other during atherosclerotic process. The serum level of sCD146 is correlated independently with plaque vulnerability.
探讨可溶性CD146（sCD146）循环水平与颈动脉粥样硬化（CAS）患者斑块易损性或炎症因子之间的关系。
纳入40例颈动脉狭窄（≥70%）的CAS患者，通过超声成像分为稳定斑块组和不稳定斑块组。另纳入40例健康受试者作为对照组。采用双抗体夹心酶联免疫吸附测定（ELISA）法检测血清sCD146和基质金属蛋白酶-9（MMP-9）水平，分析sCD146与MMP-9及高敏C反应蛋白（hs-CRP）的相关性，并评估sCD146是否与斑块易损性相关。
与健康对照组相比，CAS患者可溶性CD146水平升高[（212±43）对（173±36）ng/ml，P<0.001]。不稳定斑块的CAS患者sCD146水平显著高于稳定斑块患者[（218±28）对（176±25）ng/ml，P<0.001]。sCD146与高敏C反应蛋白（hsCRP，r = 0.370 9，P = 0.018 5）相关，hsCRP是CAS炎症的一个著名标志物。它也是斑块易损性的独立危险因素（OR = 1.16，95%CI：1.020 - 1.310，P = 0.019 2）。其水平与CAS的危险因素如年龄、同型半胱氨酸、甘油三酯、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）或高密度脂蛋白胆固醇（HDL-C）无关（P>0.05）。但与CAS患者血清MMP-9水平有良好相关性（r = 0.677 2，P<0.001）。
CAS患者可溶性CD146浓度与hsCRP和MMP-9呈正相关。在动脉粥样硬化过程中，炎症和新生血管形成可能相互作用。sCD146血清水平与斑块易损性独立相关。
